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Case Report
Congenital Giant Juvenile Xanthogranuloma, Let It Be
Michael Carletti, DO1; Daniel A. Nguyen DO, PharmD1; Joseph S. Susa, DO2;
Stephen E. Weis, DO1

Abstract

Author affiliations are listed
at the end of this article.
Correspondence to:

Description

Daniel Nguyen, DO, PharmD

Juvenile xanthogranuloma (JXG) is a rare type of non-Langerhans cell histiocytosis. JXGs
are benign and have a self-limiting course generally lasting 6 months to 3 years, with some
reported durations longer than 6 years. We present a rarer congenital giant variant, defined
as lesions with a diameter larger than 2 cm. It is uncertain if the natural history of giant xanthogranulomas is similar to the usual JXG. We followed a 5-month-old patient with a 3.5 cm
in diameter, histopathologically-confirmed, congenital, giant JXG located on the right side
of her upper back. The patient was seen every 6 months for 2.5 years. At 1 year of age, the
lesion had decreased in size, lightened in color, and was less firm. At 1.5 years old, the lesion
had flattened. By 3 years old, the lesion had resolved but left a hyperpigmented patch with a
scar at the punch biopsy site. Our case represents a congenital giant JXG that was biopsied
to confirm the diagnosis and then monitored until resolution. This case supports the clinical
course of giant JXG not being affected by the larger lesion size and that aggressive treatments or procedures are not warranted.
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Introduction

Juvenile xanthogranuloma (JXG) is a benign
proliferative disorder of histiocytes. While rare,
it is the most common type of non-Langerhans
cell histiocytosis (LCH). The incidence of JXG is
unknown. A survey of 117 dermatologists, with
an average of 12 years of practice in pediatric disease, reported a low frequency of the
disease of approximately 2 new cases yearly.1
Among those diagnosed with JXG, some may
encounter ocular complications. Of these 2371
cases of JXG, there were only 7 cases of intraocular JXG.1 JXG usually occurs in infants and
young children, typically involving the head,
neck, and upper body. The disease presents
as solitary or multiple red or brown papules,
plaques, or nodules with a yellowish hue.
Touton giant cells are a characteristic finding
in histology.2 Cutaneous lesions of JXG most
often spontaneously resolve with an unremarkable course.3 Special stains are usually only per-

formed in atypical cases to avoid unnecessary,
aggressive procedures and to rule out other
tumors with a less favorable prognosis.4,5
There are multiple clinical variations of JXG
that are even rarer. These variations have been
described as keratotic, plaque-like, and giant.6
Our case represents a congenital, giant JXG
that was biopsied to confirm the diagnosis and
then monitored for resolution, with only hyperpigmentation remaining. Per Ladha and Haber,
there have only been 51 cases of giant JXG
reported in the English literature.7 The natural history of giant JXG is uncertain as most
reported cases have not included long-term
follow-up.

Case Description

Our patient presented as a 5-month-old female for evaluation of a lesion on the right side
of her upper back that was present at birth
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and had been growing in conjunction with the
patient’s normal growth development. She was
born healthy, without complications, and was
developing normally otherwise.
Upon examination, we discovered a firm, freely
mobile 3.5 cm disc-shaped subcutaneous
nodule with a yellow, peau d’orange surface, a
violaceous vascular-appearing halo, and a central depression (Figure 1). The elevation of the
lesion measured 6 mm. She was then sent for
a Doppler ultrasound of the lesion to rule out
a vascular component. Vascular studies confirmed a non-pulsatile lesion.
She returned to the clinic, and a 4-mm punch
biopsy was performed. Histopathological studies revealed foamy histiocytes, and a few Touton giant cells were observed. Langerhans cell
histiocytosis was excluded, and the diagnosis
of giant JXG was confirmed through immunohistochemistry. The lesion stained positive for
CD68 and factor XIIIa (Figure 2). At that time,
we recommended no further treatment and
followed the patient every 6 to 12 months.
At 1 year of age, the lesion had decreased in
size, lightened in color, and was less firm. At
1.5 years old, the lesion had flattened and was
an orange-red color. By 3 years old, the lesion
had resolved with a remaining hyperpigmented
patch and a scar at the biopsy site (Figure 3).

Discussion

JXG is the most common type of non-LCH.
JXG usually occurs in infants and young children and typically involves the head, neck, and
upper body. They present as solitary or multiple red or brown papules, plaques, or nodules
with a yellowish hue.2,8 Multiple unusual clinical
variants have been described, including keratotic, plaque-like, and giant JXG. These clinical
variants are histologically indistinguishable.6
Case reports in the medical literature support a
similar natural history.9 However, there are few
reports regarding the natural history of giant
JXG. Giant JXGs are slightly more prevalent in
males and appear within the first year of life in
almost 75% of the cases, while 15% are present
at birth.2 Lesions with a diameter larger than
2 cm are classified as giant JXG.7 In contrast,
non-giant JXGs have a female predominance
and are most often found on the proximal
extremities or upper back.4 The cause of JXG is
unknown, but it is often considered a reactive
process, with histiocytes responding to traumatic or infectious stimuli.10
The course of JXG in patients with skin-limited disease is typically benign and self-limited.
These lesions usually regress within 6 months
to 3 years without any treatment.9 Hyperpigmentation and mild anetoderma or atrophy
may be present afterward.3 Giant JXG is a rare
variant, and little is known about its natural

Figure 1. Congenital giant JXG is shown at initial presentation with a 3.5 cm lesion on the right
upper back of a 5-month-old female.
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Figure 2. A biopsy shows a dermal histiocytic infiltrate. Multiple foamy (xanthomatous) histiocytes can be seen. Touton giant cells are a characteristic finding (indicated by arrows). (20x magnification)
history. In our case report, we observed the
resolution of a giant JXG within 3 years. This
outcome is not a universal finding, as 2 cases
of giant JXG have been reported, both lasting greater than 6 years without resolution.11,12
In one case, a 10-year-old Japanese male had
JXG lesions on his arms and face since he was
6 months old. The arm lesions improved, but
his facial lesions were constant and did not
improve.11 In another case, a 7-year-old Polynesian female also had JXG lesions since she was
6 months old, which had continued to evolve

until she was 1 year old. Her lesions stayed constant without any resolution.12
No treatment is required for cutaneous JXG
as the lesions are usually self-limited. Despite
their anticipated spontaneous resolution,
lesions are occasionally removed for cosmetic
purposes or functional concerns based on their
location.2
The pathology of JXG and its multiple variants
will demonstrate a dense infiltrate of his-

Figure 3. By the age of 3, there was resolution of the lesion with only a hyperpigmented patch
remaining along with a scar at the punch biopsy site.
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tiocytes, with small lesions in the superficial
dermis and large lesions extending deeper into
the subcutis. Evolving JXG lesions can account
for variations in the histiocytes, which develop
lipids in their cytoplasm as they mature and
create a foamy xanthomatous appearance.
Touton giant cells are a characteristic finding.
However, they are not required and may be
infrequent or even absent in early lesions or
lesions associated with systemic disease.2 JXG
typically has eosinophils, lymphocytes, and
plasma cells admixed.13
Immunohistochemically, JXG stain positive with
non-LCH histiocyte markers such as CD68 and
factor XIIIa, while CD1a and Langerin (CD207)
are always negative. In contrast, LCH cells are
always CD1a and CD207 positive and usually
CD68 negative.6,14 Another Langerhans group
disorder, Erdheim-Chester disease (ECD),
stains CD68 and CD163 positive, while CD1a
stains are negative. Ultrastructural analysis by
electron microscopy would show an absence of
Birbeck granules in JXG and ECD but positive
detection in LCH.13
The diagnosis may be difficult, and it is important to differentiate JXG from the other
non-LCH and LCH disorders. Under the revised
classification of histiocytoses and neoplasms
of the macrophage-dendritic cell lineages, JXG
was classified in the “C” group, also known
as cutaneous and mucocutaneous diseases.13
Histopathologic confirmation is recommended
to avoid unnecessary, aggressive procedures
and to rule out other tumors with a less favorable prognosis.4 Typically, LCH tends to show
more epidermotropism of Langerhans cells and
lacks Touton giant cells and lipidized cells. LCH
also shows characteristic “coffee bean nuclei.”
The grouping of clinical and histopathologic
features allows for differentiation between
JXG and either benign cephalic histiocytosis or
generalized eruptive histiocytoma. JXG can be
differentiated from LCH through immunohistochemistry.15,16
JXG most often occurs in the skin, but any
organ can be involved. The eye is the most
common site of extra-cutaneous involvement
affecting the unilateral iris. Ocular involvement
occurs at an incidence of 0.3-0.5% and is associated with the risk of glaucoma and subsequent blindness.1 Routine ocular exams are
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controversial given the low incidence. However,
they are deemed prudent in patients less than
2 years of age who have multiple skin lesions
due to an increased risk of involvement.3
There has been an association of JXG with
café-au-lait macules and juvenile myelomonocytic leukemia (JML).2 Patients with multiple
café-au-lait macules are at increased risk of
neurofibromatosis Type 1 (NF1), which has
also been found to have an increased risk of
JML.17 A “triple association” has been observed
in patients with JXG, NF1, and JML. Patients
with both JXG and NF1 have an increased risk
(20-32 fold) of developing JML, with a reported
observed frequency of 1/1.05 x 106.15,17

Conclusion

This case illustrates a rare giant congenital variant of a JXG, the most common type of nonLCH. Lesions larger than 2 cm are classified as
giant and rarely reported. The lesions are often
misdiagnosed, as a variety of clinical presentations have been described including exophytic,
polypoid, atrophic plaque, mass with peripheral
papules, and even ulceration. Our case report
appears to show that large lesion size does not
affect the generally accepted clinical course for
skin-limited JXG regression. Regression typically ranges from 6 months to 3 years, though
lesions persisting beyond 6 years have been
reported.4 Histopathologic confirmation is
recommended to avoid unnecessary, aggressive
procedures and to rule out other tumors with a
less favorable prognosis. We show the importance of recommending a management plan
of close monitoring and no further treatment
or procedures. Our patient only had a remaining hyperpigmented patch where a congenital
giant JXG once occupied the majority of the
right side of her upper back.
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